November 2021 Examples of media coverage: Woman’s own immune system has possibly cured her of HIV - Benjamin Ryan, NBC News, November 15, 2021 Scientists report finding a second person to be ‘naturally’ cured of HIV, raising hopes for future…
November 2021 Examples of media coverage: Research team develops vaccine that kills HIV in monkeys - The Asahi Shimbun, November 9, 2021 A New Vaccine Kills HIV in Monkeys. And It's Coming to Humans in 5 Years - Interesting Engineering,…
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.
In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.
Two recent developments have brought renewed publicity to proposals to conduct human challenge studies to test COVID-19 vaccine candidates: an open letter from the organization 1DaySooner and media reports that Adrian Hill’s Oxford University research group is planning a challenge study, taking advantage of the lack of regulatory oversight of human challenge experiments in the United Kingdom.
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.